The somatostatin-2 receptor is heterogeneously expressed in paragangliomas and pheochromocytomas, especially in those with SDHx mutations [29,30], and we speculate that this may influence the treatment response to PRRT. This evidence concerns the gene SSTR2 and hereditary pheochromocytoma-paraganglioma.